Loading
A phase 2 trial of Patritumab deruxtecan in melanoma and cervical cancer, run by Daiichi Sankyo, now recruiting.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06172478 by Daiichi Sankyo, with 740 participants planned, started 2024-02-26 and due to reach its primary completion in 2027-09-01. Interventions recorded: HER3-DXd. Conditions listed: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Daiichi Sankyo, Endometrial cancer, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Patritumab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/